title: The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk.
abstract: Weekly administration of teriparatide has been shown to reduce the risk of vertebral and non-vertebral fractures in patients with osteoporosis at higher fracture risk in Japan. However, its efficacy for hip fracture has not been established. To gain insight into the effect of weekly teriparatide on the hip, hip structural analysis (HSA) based on dual-energy X-ray absorptiometry (DXA) was performed using the data of 209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks. The DXA scans, obtained at baseline, 48 weeks and 72 weeks, were analyzed to extract bone mineral density (BMD) and cross-sectional geometrical indices at the narrowest point on the neck (NN), the intertrochanteric region (IT), and the proximal shaft. Compared with placebo after 72 weeks, the teriparatide group showed significantly higher BMD, average cortical thickness, bone cross-sectional area, and section modulus, and lower buckling ratio at both the NN and IT regions. No significant expansion of periosteal diameter was observed at these regions. There were no significant differences in BMD and HSA indices at the shaft region. The results indicate that overall structural strength in the proximal femur increased compared to placebo, suggesting that once-weekly teriparatide effectively reverses changes in hip geometry and strength with aging.
authors.affiliation: Department of Nuclear Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan. Electronic address: tsone@med.kawasaki-m.ac.jp.
authors.forename: Teruki
authors.initials: T
authors.lastname: Sone
authors.affiliation: Medical Work-Life-Balance Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Electronic address: masako@nagasaki-u.ac.jp.
authors.forename: Masako
authors.initials: M
authors.lastname: Ito
authors.affiliation: Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan. Electronic address: dean@med.kawasaki-m.ac.jp.
authors.forename: Masao
authors.initials: M
authors.lastname: Fukunaga
authors.affiliation: Department of Radiological Technology, Kawasaki College of Allied Health Professions, 316 Matsushima, Kurashiki, Okayama 701-0194, Japan. Electronic address: t-tomo@jc.kawasaki-m.ac.jp.
authors.forename: Tatsushi
authors.initials: T
authors.lastname: Tomomitsu
authors.affiliation: Internal Medicine 1, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan. Electronic address: sugimoto@med.shimane-u.ac.jp.
authors.forename: Toshitsugu
authors.initials: T
authors.lastname: Sugimoto
authors.affiliation: Research Institute and Practice for Involutional Diseases, 1610-1 Meisei, Misato, Azumino, Nagano 399-8101, Japan. Electronic address: ripid@fc4.so-net.ne.jp.
authors.forename: Masataka
authors.initials: M
authors.lastname: Shiraki
authors.affiliation: Medical Affairs Department, Asahi-Kasei Pharma Corporation, 1-105, Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101, Japan. Electronic address: yoshimura.th@om.asahi-kasei.co.jp.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yoshimura
authors.affiliation: National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. Electronic address: t-nak@utopia.ocn.ne.jp.
authors.forename: Toshitaka
authors.initials: T
authors.lastname: Nakamura
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010919:Placebos; D012307:Risk Factors; D019379:Teriparatide / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D010919:Placebos; D019379:Teriparatide
keywords: Hip geometry; Hip structural analysis; Osteoporosis; Teriparatide; Weekly injection